why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
First received: April 18, 2025

Clinical Trial: Ropeginterferon for Treatment Free Remission

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: CML (Chronic Myelogenous Leukemia)

Study Type: INTERVENTIONAL


Official Title: A Feasibility Study of Ropeginterferon for Treatment Free Remission in CML Patients Who Have a Sustained Deep Molecular Response

Brief Summary: Ropeginterferon is a long-acting next-generation mono-pegylated interferon alfa-2b consisting of one isoform produced by PharmaEssentia Co. and the pegylated (PEG) formulations that require less frequent administration and have improved efficacy and tolerability.In this study, patients in the investigational arm will receive Ropeginterferon subcutaneously with 250 ?g at week 0, 350 ?g at week 2, 500 ?g at week 4, and thereafter 500 ?g bi-weekly until week 24.

Read more